NASDAQ:IBIO iBio Q1 2026 Earnings Report $1.42 +0.02 (+1.43%) Closing price 08/3/2026 04:00 PM EasternExtended Trading$1.42 0.00 (0.00%) As of 08/3/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast iBio EPS ResultsActual EPS-$0.11Consensus EPS -$0.07Beat/MissMissed by -$0.04One Year Ago EPSN/AiBio Revenue ResultsActual Revenue$0.10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AiBio Announcement DetailsQuarterQ1 2026Date11/12/2025TimeAfter Market ClosesConference Call DateWednesday, November 12, 2025Conference Call Time4:00PM ETUpcoming EarningsiBio's Q4 2026 earnings is estimated for Friday, September 4, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) iBio Earnings HeadlinesiBio Updates Governance Deadlines for 2026 Annual MeetingJuly 17, 2026 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)July 3, 2026 | theglobeandmail.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. | Altimetry (Ad)iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP StudyJuly 1, 2026 | globenewswire.comCould iBio (IBIO) Be an Underrated Obesity Stock?June 11, 2026 | insidermonkey.com5 Under-the-Radar AI Stocks to Buy in 2026June 11, 2026 | insidermonkey.comSee More iBio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like iBio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on iBio and other key companies, straight to your email. Email Address About iBioiBio (NASDAQ:IBIO), a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.View iBio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have ControlStrategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31A Sweet Beat and a Wearables Rally Came With Reasons to PauseChevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong Signal Upcoming Earnings Spotify Technology (8/4/2026)SpaceX (8/4/2026)Electronic Arts (8/4/2026)McDonald's (8/4/2026)Toyota Motor (8/4/2026)Coca-Cola Europacific Partners (8/4/2026)BP (8/4/2026)EOG Resources (8/4/2026)Energy Transfer (8/4/2026)Marathon Petroleum (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
